Nutrition for the liver transplant patient

Antonio J. Sanchez, Jaime Aranda‐Michel – 24 August 2006 – Patients with end‐stage liver disease (ESLD) frequently have diverse abnormalities of carbohydrate, lipid, and protein metabolism that cause progressive deterioration of their clinical condition and lead to malnutrition. Malnutrition is almost universally present in patients with ESLD undergoing liver transplantation and has been associated with increased morbidity and mortality.

Antituberculous therapy–induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy

Ramazan Idilman, Sadik Ersoz, Sahin Coban, Ozlem Kumbasar, Hakan Bozkaya – 24 August 2006 – Standard antituberculous therapy including isoniazid, rifampin, ethambutol, and pyrazinamide is widely used for the treatment of active tuberculosis. Its most important side effect is hepatotoxicity, ranging from asymptomatic transaminitis to fulminant hepatic failure. A 19‐year‐old woman was admitted to our unit due to jaundice and unconsciousness. According to her past medical history, she was diagnosed as having extrapulmonary tuberculosis and had been prescribed standard antituberculous therapy.

Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases

Ludivine Falize, Anne Guillygomarc'h, Michele Perrin, Fabrice Lainé, Dominique Guyader, Pierre Brissot, Bruno Turlin, Yves Deugnier – 26 July 2006 – The current study was undertaken to assess whether fibrosis could regress under venesection therapy in patients with C282Y homozygous genetic hemochromatosis. The 36 patients studied were recruited from a subfile of our database consisting of 125 C282Y homozygotes with either severe fibrosis or cirrhosis (F3 or F4 fibrosis stage, respectively, according to the METAVIR grading system).

Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Ulrich Spengler, Dietrich Hüppe, Bernd Möller, Heinz‐Hubert Feucht, Bertram Wiedenmann, Thomas Berg – 26 July 2006 – Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients with lamivudine‐resistant hepatitis B virus (HBV) infection and may be associated with developing resistance and disease progression. We therefore investigated whether the efficacy of viral suppression could be improved by replacing ADV with tenofovir disoproxil fumarate (TDF).

Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low‐risk population

Lu‐Yu Hwang, Jennifer R. Kramer, Catherine Troisi, Lara Bull, Carolyn Z. Grimes, Rob Lyerla, Miriam J. Alter – 26 July 2006 – We conducted an anonymous cross‐sectional seroprevalence study of a population with a low frequency of injection drug use to determine whether persons with a history of cosmetic procedures, such as tattooing and body piercing, or intranasal drug use were at increased risk for hepatitis C virus (HCV) or hepatitis B virus (HBV) infection. Students 18 years and older from eight college campuses in Houston, Texas, were invited to participate in the study.

Correlation between beta‐lipoprotein levels and outcome of hepatitis C treatment

Kavitha Gopal, Timothy C. Johnson, Saraswathi Gopal, Aaron Walfish, Christine T. Bang, Pauline Suwandhi, Helene N. Pena‐Sahdala, David J. Clain, Henry C. Bodenheimer, Albert D. Min – 26 July 2006 – The low‐density lipoprotein receptor (LDLR) has been proposed as a candidate receptor for the hepatitis C virus (HCV). Competitive inhibition of HCV binding to the LDLR by low‐density lipoprotein (LDL) has been shown in vitro.

Subscribe to